The phenotype of Graves' orbitopathy is associated with thyrotropin receptor antibody levels.
Binding immunoassay
Cell-based bioassay
Graves’ orbitopathy
Ophthalmological features
Stimulating antibodies
Thyrotropin receptor antibodies
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
03
02
2023
accepted:
30
03
2023
medline:
9
10
2023
pubmed:
6
4
2023
entrez:
5
4
2023
Statut:
ppublish
Résumé
Graves' orbitopathy (GO) is a specific inflammatory disorder of the orbit characterized by a highly heterogeneous clinical phenotype. The role of thyrotropin receptor antibodies (TSH-R-Ab) has been widely researched, however there is still no evidence that these antibodies have a direct pathogenic role in this pathology. The aim of this study was to examine their relation to the individual clinical features of GO. Ninety-one consecutive patients with GO were recruited. Total antibody concentration (TSH-R binding inhibitory immunoglobulins, TBII) and their functional activity (stimulating TSH-R-Ab, TSAb) were measured using binding immunoassay and cell-based bioassay, respectively. Both TSAb and TBII levels were significantly associated to the clinical parameters of GO activity. TSAb was a more sensitive serological marker compared to TBII pertaining to eyelid retraction and edema, proptosis, extra-orbital muscle disorders, diplopia, irritable eye symptoms, and photophobia. TSAb, but not TBII, was a significant predictive marker of conjunctival redness, chemosis, caruncle/plica inflammation, eye irritation, and orbital pain, (odds ratio: 3.096, p = 0.016; 5.833, p = 0.009; 6.443, p = 0.020; 3.167, p = 0.045; 2.893, p = 0.032; versus 2.187, p = 0.093; 2.775, p = 0.081; 3.824, p = 0.055; 0.952, p = 0.930; 2.226, p = 0.099, respectively). Neither TSAb nor TBII correlated with the level of proptosis (ρ = 0.259, p = 0.090, and ρ = 0.254, p = 0.104, respectively), however rising TSAb levels were strongly associated to the level of proptosis. TSH-R-Ab were significantly associated with GO's phenotype. Especially TSAb, as a sensitive and predictive serological biomarker, can improve diagnosis and management of GO.
Identifiants
pubmed: 37020104
doi: 10.1007/s40618-023-02085-5
pii: 10.1007/s40618-023-02085-5
doi:
Substances chimiques
Long-Acting Thyroid Stimulator
9034-48-4
Autoantibodies
0
Immunoglobulins, Thyroid-Stimulating
0
Receptors, Thyrotropin
0
Thyrotropin
9002-71-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2309-2317Subventions
Organisme : Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
ID : 175036
Organisme : Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
ID : 451-03-9/2021-14/200161
Informations de copyright
© 2023. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Lee ACH, Kahaly GJ (2022) Pathophysiology of thyroid-associated orbitopathy. Best Pract Res Clin Endocrinol Metab. https://doi.org/10.1016/j.beem.2022.101620
doi: 10.1016/j.beem.2022.101620
pubmed: 35459628
pmcid: 9550878
Dickinson AJ (2017) Clinical manifestations. In: Wiersinga WM, Kahaly GJ (eds) Graves’ Orbitopathy: a multisciplinary approach. Karger, Basel
Ponto KA, Binder H, Diana T, Matheis N, Otto AF, Pitz S et al (2015) Prevalence, phenotype, and psychosocial well-being in euthyroid/hypothyroid thyroid-associated orbitopathy. Thyroid 25:942–948
doi: 10.1089/thy.2015.0031
pubmed: 26244413
Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML (2020) Epidemiology, natural history, rrisk factors, and prevention of Graves’ orbitopathy. Front Endocrinol 11:615993
doi: 10.3389/fendo.2020.615993
Bahn RS (2015) Current Insights into the Pathogenesis of Graves’ ophthalmopathy. Horm Metab Res 47:773–778
doi: 10.1055/s-0035-1555762
pubmed: 26361262
Bahn RS (2010) Graves’ ophthalmopathy. N Engl J Med 362:726–738
doi: 10.1056/NEJMra0905750
pubmed: 20181974
pmcid: 3902010
Adams DD (1988) Long-acting thyroid stimulator: how receptor autoimmunity was discovered. Autoimmunity 1:3–9
doi: 10.3109/08916938808997170
pubmed: 2979603
Kahaly GJ, Diana T, Olivo PD (2020) TSH receptor antibodies: relevance & utility. Endocr Pract 26:97–106
doi: 10.4158/EP-2019-0363
pubmed: 32022598
Diana T, Ponto KA, Kahaly GJ (2021) Thyrotropin receptor antibodies and Graves’ orbitopathy. J Endocrinol Invest 44:703–712
doi: 10.1007/s40618-020-01380-9
pubmed: 32749654
Kahaly GJ, Diana T (2017) TSH Receptor antibody functionality and nomenclature. Front Endocrinol 8:28
doi: 10.3389/fendo.2017.00028
Gerding MN, Van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF (2000) Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol 52:267–271
doi: 10.1046/j.1365-2265.2000.00959.x
Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C (2021) The 2021 European group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 185:G43-67
doi: 10.1530/EJE-21-0479
pubmed: 34297684
Dickinson AJ, Perros P (2001) Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 55:283–303
doi: 10.1046/j.1365-2265.2001.01349.x
pubmed: 11589671
Smith TJ (2010) Pathogenesis of Graves’ orbitopathy: a 2010 update. J Endocrinol Invest 33:414–421
doi: 10.1007/BF03346614
pubmed: 20631493
pmcid: 6779038
Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH (2018) 2018 European thyroid association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 7:167–186
doi: 10.1159/000490384
pubmed: 30283735
pmcid: 6140607
Nedeljkovic Beleslin B, Ciric J, Stojkovic M, Savic S, Lalic T, Stojanovic M et al (2020) Comparison of efficacy and safety of parenteral versus parenteral and oral glucocorticoid therapy in Graves’ orbitopathy. Int J Clin Pract 74:e13608
doi: 10.1111/ijcp.13608
pubmed: 32649036
Bahn RS, Gorman C (1987) Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 16:391–407
doi: 10.1016/S0889-8529(18)30485-7
pubmed: 3319588
Wiersinga W, Žarković M, Bartalena L, Donati S, Perros P, Okosieme O et al (2018) EUGOGO (European Group on Graves’ Orbitopathy). Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur J Endocrinol 178:635–643. https://doi.org/10.1530/EJE-18-0039
doi: 10.1530/EJE-18-0039
pubmed: 29650691
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Grave’s ophthalmopathy. Clin Endocrinol (Oxf) 47:9–14
doi: 10.1046/j.1365-2265.1997.2331047.x
pubmed: 9302365
Lytton SD, Li Y, Olivo PD, Kohn LD, Kahaly GJ (2010) Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol 162:438–446
doi: 10.1111/j.1365-2249.2010.04266.x
pubmed: 21070207
pmcid: 3026547
Leschik JJ, Diana T, Olivo PD, König J, Krahn U, Li Y et al (2013) Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol 139:192–200
doi: 10.1309/AJCPZUT7CNUEU7OP
pubmed: 23355204
Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S et al (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470
doi: 10.1210/jc.2005-2813
pubmed: 16835285
Sarić Matutinović M, Diana T, Nedeljković Beleslin B, Ćirić J, Žarković M, Kahaly GJ et al (2022) Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves’ orbitopathy. J Endocrinol Invest 45:189–197. https://doi.org/10.1007/s40618-021-01652-y
doi: 10.1007/s40618-021-01652-y
pubmed: 34324163
Sarić-Matutinović M, Diana T, Nedeljković-Beleslin B, Ćirić J, Žarković M, Perović-Blagojević I et al (2022) Sensitivity of three thyrotropin receptor antibody assays in thyroid-associated orbitopathy. J Med Biochem 41:211–220. https://doi.org/10.5937/jomb0-34718
doi: 10.5937/jomb0-34718
pubmed: 35510209
pmcid: 9010037
Wiersinga WM, Smit T, van der Gaag R, Mourits M, Koornneef L (1989) Clinical presentation of Graves’ ophthalmopathy. Ophthalmic Res 21:73–82
doi: 10.1159/000266782
pubmed: 2786616
Kendler DL, Lippa J, Rootman J (1993) The initial clinical characteristics of Graves’ orbitopathy vary with age and sex. Arch Ophthalmol 111:197–201
doi: 10.1001/archopht.1993.01090020051022
pubmed: 8431156
Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP et al (2002) Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87:385–392
doi: 10.1210/jcem.87.1.8164
pubmed: 11788681
Bruscolini A, Sacchetti M, La Cava M, Nebbioso M, Iannitelli A, Quartini A et al (2018) Quality of life and neuropsychiatric disorders in patients with Graves’ orbitopathy: current concepts. Autoimmun Rev 17:639–643
doi: 10.1016/j.autrev.2017.12.012
pubmed: 29729448
Anderton LC, Neoh C, Walshaw D, Dickinson AJ. 2000 Reproducibility of clinical assessment in thyroid eye disease. Abstract of the European Society of the Ophthalmic Plastic and Reconstructive Surgery. Paris
Marinò M, Ionni I, Lanzolla G, Sframeli A, Latrofa F, Rocchi R et al (2020) Orbital diseases mimicking Graves’ orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest 43:401–411
doi: 10.1007/s40618-019-01141-3
pubmed: 31691261
Kahaly GJ, Wüster C, Olivo PD, Diana T (2019) High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with Graves’ disease. J Clin Endocrinol Metab 104:2561–2568. https://doi.org/10.1210/jc.2018-02705
doi: 10.1210/jc.2018-02705
pubmed: 30753531
Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ (2011) Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology 118:2279–2285. https://doi.org/10.1016/j.ophtha.2011.03.030
doi: 10.1016/j.ophtha.2011.03.030
pubmed: 21684605
Nicolì F, Lanzolla G, Mantuano M, Ionni I, Mazzi B, Leo M et al (2021) Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy. J Endocrinol Invest 44:581–585. https://doi.org/10.1007/s40618-020-01353-y
doi: 10.1007/s40618-020-01353-y
pubmed: 32648002
Goh SY, Ho SC, Seah LL, Fong KS, Khoo DH (2004) Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves’ disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol 60:600–607
doi: 10.1111/j.1365-2265.2004.02033.x
Volpe R (1994) Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. Thyroid 4:217–223. https://doi.org/10.1089/thy.1994.4.217
doi: 10.1089/thy.1994.4.217
pubmed: 7522684
Kampmann E, Diana T, Kanitz M, Hoppe D, Kahaly GJ (2015) Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active Graves’ orbitopathy: a prospective study. Int J Endocrinol. https://doi.org/10.1155/2015/678194
doi: 10.1155/2015/678194
pubmed: 26221139
pmcid: 4499387